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The gene clusters of several glycopeptides contain
genes that encode COG2120 domain zinc-depen-
dent N-acetylglucosaminyl deacetylases. Recently,
a COG2120 protein encoded in the chloroeremomy-
cin gene cluster, Cep15, has been postulated to pos-
sess nucleotidyltransferase activity. Here, we dem-
onstrate that Cep15 possesses no catalytic activity
and does not have a clear role in chloroeremomycin
biosynthesis. This result strongly suggests that
cep15 and bal2 are evolutionary artifacts and may
be pseudogenes. Comparative sequence analysis
with the closely related active Orf2* deacetylase
(teicoplanin biosynthesis) reveals an asparagine in
place of a metal-binding histidine in the ‘‘pseudo-
active site’’ of Cep15. Substitution of this histidine
by asparagine in Orf2* abolishes deacetylase activ-
ity. Remarkably, the Cep15 N164H mutant is an
active deacetylase. To our knowledge, this is the first
example of reactivating an ancestral enzymatic role
for a bacterial protein by point mutagenesis.
INTRODUCTION
Glycopeptides are an important class of antibiotics whose most
important application is in the treatment of multidrug-resistant
bacterial infections. Thus far, the gene clusters of six glycopep-
tides (chloroeremomycin, balhimycin, complestatin, A40926,
A47934, and teicoplanin) have been sequenced (van Wagenin-
gen et al., 1998; Pelzer et al., 1999; Chiu et al., 2001; Pootoolal
et al., 2002; Sosio et al., 2004; Li et al., 2004). These gene clus-
ters contain a number of common elements that imply a shared
evolutionary origin for these structurally complex natural prod-
ucts (Donadio et al., 2005). One gene shared among all glycosy-
lated glycopeptides (chloroeremomycin, balhimycin, A40926,
and teicoplanin), but not with the unglycosylated teicoplanin-
like A47934, encodes a COG2120 domain protein (cep15, bal2,
dbv21, and orf2*, respectively; Figure 1B). In this paper, bal2/
Bal2 is used to denote orf2/Orf2 (NCBI accession number476 Chemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier LtdCAC48365) from the balhimycin gene cluster to remove any
ambiguity between it and orf2*/Orf2* (NCBI accession number
CAG15014) from the teicoplanin gene cluster. Recently, proteins
that contain this domain (and the related PF02585 domain) have
been identified as N-deacetylases that act on an N-acetylgluco-
saminyl group (Truman et al., 2006, 2007).
A glucosaminyl group features in almost every natural product
whose gene cluster encodes a protein with COG2120 domain
architecture (Truman et al., 2007). Chloroeremomycin and balhi-
mycin represent two rare exceptions to this observation
(proteins Cep15 and Bal2, respectively). They are decorated
with glucose and vancosamine-like sugars that derive from
uridine or thymidine diphospho-glucose (UDP-Glc or TDP-Glc;
NDP-Glc will be used here to denote either of these activated
sugars). The vancosamine pathway is well characterized and
does not require a deacetylase (Chen et al., 2000). Recently,
Cep15 (NCBI accession number CAA11778) has been proposed
to function as a glucose-1-phosphate thymidylyltransferase in
the biosynthesis of chloroeremomycin (Ho et al., 2006). BtrD,
a COG2120 protein encoded by the butirosin gene cluster, was
also initially characterized as a nucleotidyltransferase (Kudo
et al., 2005), a logical functional assignment given its implied
role in sugar biosynthesis. However, we have recently revised
the function of BtrD to a deacetylase (Truman et al., 2007),
a role that is consistent with all other characterized homologs.
NDP-Glc is an activated sugar that is involved in an array of
essential primary metabolic pathways. Consequently, although
a glucose-1-phosphate nucleotidyltransferase would not be
without precedent in secondary metabolism (MtmD in mithramy-
cin biosynthesis, for example) (Lombo´ et al., 1997), the activated
sugar is abundantly synthesized by bacteria, so it is likely that
a dedicated nucleotidyltransferase encoded in the gene cluster
is not essential for glycopeptide biosynthesis. The intracellular
concentration of NDP-Glc has been estimated to be as high as
0.8 mM (Bochner and Ames, 1982). Additionally, Cep15 and
Bal2 contain very significant sequence similarity to the charac-
terized deacetylases Orf2* and Dbv21 (these four proteins
possess over 65% identical amino acid residues). This similarity
makes their role as nucleotidyltransferases unexpected, espe-
cially because it appears to be accompanied by no significant
change in the protein’s predicted two- or three- dimensional
structure (Bennett-Lovsey et al., 2008).All rights reserved
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transferase and has no discernible function in the biosynthesis of
chloroeremomycin. Its in vitro inactivity is supported by gene
knockout studies. Inactivation of the closely related bal2 gene
in the balhimycin gene cluster resulted in no change of pheno-
type, whereas inactivation of the previously in vitro characterized
orf2* gene from the teicoplanin gene cluster resulted in the
expected production of teicoplanin pathway intermediates. In
addition, a single point mutation has been identified that has
deactivated Cep15 from its role as a deacetylase. Remarkably,
mutagenesis at this position converts Cep15 into a functional
N-acetylglucosaminyl deacetylase. The evolutionary implica-
tions of this result are discussed.
RESULTS
Analysis of Cep15 for Nucleotidyltransferase
and Deacetylase Activity
The cep15 gene was cloned from cosmid DNA and inserted
into the pET28a(+) expression vector; Cep15 was expressed
Figure 1. Glycopeptides Whose Gene
Clusters Contain a Gene Encoding a
COG2120 Domain Protein
(A) Structures of glycopeptides. Amino acids on
chloroeremomycin are numbered aa 1 to aa 7.
(B) Comparison of COG2120 genes (shaded dark
gray) within glycopeptide gene clusters.
in Escherichia coli BL21(DE3) as an
N-terminally hexahistidine-tagged pro-
tein. During our characterization of Orf2*,
low-level nucleotidyltransferase activity
was detected when the protein was not
sufficiently purified (Truman et al., 2006).
Ho and colleagues (2006) have reported
that Cep15 has a kcat for nucleotidyltrans-
ferase activity of 0.01 s1. It is possible
that this low activity may be generated
by a trace amount of a coeluting nucleoti-
dyltransferase produced by the host
E. coli rather than by Cep15.
To assess the ability of Cep15 to func-
tion as a glucose-1-phosphate thymidy-
lyltransferase, the protein was purified
by eluting from a Ni2+-affinity column
using a stepwise increases in imidazole
concentration, then by size exclusion
chromatography (see Figure S1 in the
Supplemental Data available with this
article online). This strategy progressively
removes proteins that nonspecifically
bind to the Ni2+-affinity resin, so activity
due to impurities should decrease with
increasing imidazole concentrations.
Each fraction (50 mM protein per assay)
was tested for nucleotidyltransferase
activity with thymidine 50-triphosphate
(TTP) and glucose-1-phosphate. The separation of thymidine
50-diphosphate (TDP) and TDP-Glc by HPLC proved problem-
atic, so an ion-pairing negative-detection LC/ESI-MS strategy
using triethylammonium acetate was adopted to distinguish
between these compounds. Low-level nucleotidyltransferase
activity was detected only in the comparatively impure 10 mM
imidazole fraction (observed [M  H] = 562.9 at 13.3 min;
predicted [M  H] = 563.1). A higher level of nucleotide triphos-
phatase (NTPase) activity was actually observed with the gener-
ation of TDP ([M  H] = 400.9 at 13.3 min; predicted [M  H] =
401.0). This activity diminishes as the imidazole concentration
(and therefore Cep15 purity) is increased. Activity with uridine
50-triphosphate (UTP) was also assessed and this resulted in
similar NTPase activity (UTP converted to UDP) and no nucleo-
tidyl transfer. Nucleotidyltransferases and NTPases are two
abundant and important classes of enzymes, so it is not surpris-
ing that the host E. coli produces them in a significant amount.
Given the inability of Cep15 to function as a nucleotidyltrans-
ferase and its significant sequence identity to functional
deacetylases, it is possible that it is an active yet redundant de-
acetylase. Additionally, it is possible, if not likely, that the glucoseChemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier Ltd All rights reserved 477
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uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) rather
than NDP-Glc. This inefficient pathway is observed in the biosyn-
thesis of kanamycin A (Kojima et al., 1968, 1969). However, this
relies on the deamination of the deacetylated amine (via trans-
amination-reduction), and the chloroeremomycin gene cluster
does not encode appropriate enzymes for this transformation.
More significantly, NDP-glucose has been identified as the
native substrate for the glycosyltransferase GtfB that glycosy-
lates aa 4 (Losey et al., 2001).
The ability of Cep15 to function as a deacetylase was
investigated by in vitro testing with UDP-GlcNAc, teicoplanin
N-acetylglucosaminyl pseudoaglycone 1, and chloroeremomy-
cin N-acetylglucosaminyl pseudoaglycone 3 (Figure 2). No de-
acylation activity was detected, strongly implying that Cep15
has lost its catalytic ability.
Inactivation of orf2* Results in a Change in Phenotype
To verify the role of Orf2* in teicoplanin biosynthesis, the orf2*
gene was inactivated by the in-frame removal of a 285 bp
fragment from Actinoplanes teichomyceticus (Figure 3A). This
deletion removes over a third of the gene, including the
161HPDH164 motif, thus removing one zinc ligand and at least
one substrate binding residue (see alignment, Figure 4). The de-
letion construct (pQZ12; based on pHZ1358) (Sun et al., 2002)
was introduced into the A. teichomyceticus genome by inter-
generic transfer from E. coli. Double crossover events were
screened by PCR and verified by sequencing.
Wild-type andDorf2* mutant strain supernatants were purified
using a D-Ala-D-Ala resin to specifically isolate teicoplanin deriv-
atives. LC/ESI-MS analysis revealed that the wild-type strain
produces an expected array of teicoplanins, mainly differing in
the length of theN-acyl chain attached to the glucosamine group
at aa 4 (Figure S2). In contrast, the Dorf2* mutant strain does not
produce mature teicoplanin. Instead, two new peaks appear
(Figure 3C). These peaks correspond to the doubly glycosylated
teicoplanin 2 (Figure 2) and N-acetylglucosaminyl pseudoagly-
cone 1 respectively. The identity of these compounds was con-
firmed by comparison of retention times with in vitro-produced 1
and teicoplanins A3-1 and A3-2 (data not shown). Complemen-
tation of the Dorf2* mutant strain with a plasmid-borne copy of
orf2* restored production of teicoplanin.
This result clearly demonstrates the role of Orf2* as an N-ace-
tylglucosaminyl deacetylase in the biosynthesis of teicoplanin.
No teicoplanin derivative glycosylated at aa 6 was isolated,
perhaps indicating the in vivo requirement for deacetylation or
acylation prior to glycosyltransfer to aa 6. This apparently high
specificity differs from observations made in two in vitro studies
on this glycosylation event (Li et al., 2004; Howard-Jones et al.,
2007). In vitro, there is little difference in kcat/Km values for the
aa 6 glycosyltransferase Orf1 toward pseudoaglycones 1 and 4
(Howard-Jones et al., 2007).
Deletion of bal2 Does Not Change Phenotype
Instead of removing cep15, the closely related bal2 (Figures 1
and 4) was deleted from the balhimycin producer,Amycolatopsis
balhimycina, as this strain is highly amenable to genetic manip-
ulation (Pelzer et al., 1997). A bal2 in-frame deletion mutant
(Dbal2) with an internal deletion of 219 bp was constructed and478 Chemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier Ltdverified by PCR analysis, as described elsewhere (Stegmann
et al., 2006). After cultivation in the balhimycin production media,
theA. balhimycinaDbal2mutant showed the same phenotype as
the wild-type: they grew as orange vegetative hyphae. The ability
to produce balhimycin was tested in a bioassay. The culture
filtrate of the mutant induced inhibition zones of the same diam-
eter against Bacillus subtilis as did the wild-type. This result was
confirmed by LC/ESI-MS analysis where balhimycin was identi-
fied in the culture filtrate of the mutant strains in similar amounts
as with the wild-type (100 mg l1), indicating that Bal2 is not
required for the biosynthesis of balhimycin.
Sequence Alignment Comparing Active
and Inactive Deacetylases
Comparative sequence analysis of Cep15 and Bal2 with the
characterized deacetylases Orf2* and Dbv21 is unusual because
there is very little difference between the active deacetylases
and the apparently nonfunctional proteins (Figure 4). COG2120
domain deacetylases possess an active site base (Asp18, pres-
ent in both Cep15 and Bal2) and an HXDD(X)nH zinc(II) binding
motif (where n = 90  150 and bold residues are zinc(II) ligands)
(Hernick and Fierke, 2005). In contrast, both Bal2 and Cep15
contain HXDD(X)144N, where the replacement of a histidine
with an asparagine at position 164 is the only significant active
site mutation. This subtle modification is unique to Cep15 and
Bal2 within the entire COG2120 family. Inspection of the crystal
Figure 2. N-Acetylglucosaminyl Pseudoaglycones Referred to in
This StudyAll rights reserved
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mycothiol biosynthesis (Maynes et al., 2003; McCarthy et al.,
2004), and of BcZBP, a COG2120 deacetylase from Bacillus
cereus (Fadouloglou et al., 2007), conclusively demonstrates
that His164 isa zinc(II) ligand. In addition, a divalent transition met-
al ion has been shown to be essential for activity in an array of
deacetylases including MshB (Hernick and Fierke, 2005; Newton
et al., 2006). Therefore, this active site modification may weaken
zinc(II) binding enough to inactivate a COG2120 deacetylase.
Figure 3. Inactivation of orf2* in the Teico-
planin Gene Cluster
(A) Removal of a 285 bp region from orf2*.
(B) Verification of deletion by PCR of the orf2*
region: Left to right = Marker (Hyperladder I, Biol-
ine); negative plasmid control (pQZ10); positive
plasmid control (pQZ12); wild-type genomic
DNA; Dorf2* genomic DNA.
(C) Metabolite profile of Dorf2* mutant strain (se-
lective ion monitoring for teicoplanin derivatives).
Figure 4. Comparative Sequence Alignment of the Putatively Functionless Cep15 andBal2with Characterized Deacetylases Orf2* andDbv21
Fully conserved residues have white text on a red background, and similar amino acids are framed in blue. Similar residues within a group are colored red and
residues that significantly differ from one group to another have an orange background. Metal binding residues are denoted by triangles, the active site base by
a star and substrate binding residues by circles.
Mutagenesis studies on the analogous
histidine in Trypanosoma brucei N-acetyl-
glucosaminyl phosphatidylinositol de-N-
acetylase (PIG-L) (Urbaniak et al., 2005),
a eukaryotic COG2120 domain protein,
showed that mutagenesis to alanine
reduced activity but did not fully destroy
catalysis. Our results suggest that aspara-
gine is a more debilitating residue than
alanine at this position. Alternatively, as
there may not be a high evolutionary pressure to retain a functional
Cep15, its inactivity could be due to the cumulative effect of a
number of less apparent mutations to substrate binding residues.
Assessing the Importance of Residue
164 by Mutagenesis
The importance of an asparagine at aa 164 was probed by
constructing the H164N Orf2* mutant. This mutant possesses
no deacylation activity toward either teicoplanin or 1, evenChemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier Ltd All rights reserved 479
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long reaction times (24 hr). This finding confirms that His164 is
an essential residue for catalysis and cannot be successfully
replaced by asparagine.
Given the striking effect of the Orf2* histidine to asparagine
mutation, and the apparent functional redundancy of Cep15,
the Cep15 N164H mutant was constructed in an attempt to
reconstitute deacetylase activity. This mutant was assayed
with teicoplanin and pseudoaglycones 1 and 3. Remarkably,
Cep15 N164H efficiently deacetylates both 1 and 3, producing
the glucosaminyl-pseudoaglycones 4 and 5 (Figures 5 and 6).
This activity is clearly observed by the appearance of chloroere-
momycin derivative 4 (tR = 21.7 min, Figure 5) with an observed
[M + H]+ of 1304.4 (calculated [M + H]+ = 1304.4). However, this
mutant does not deacylate teicoplanin, possibly because of its
longer acyl chain, thus providing a notable functional distinction
between Cep15 N164H and wild-type Orf2*.
This active mutant clearly demonstrates that only a single
point mutation (cytosine to adenosine) is responsible for the
disabling of Cep15 (Figure S3). In nature, similar minimal muta-
genesis to deactivate an otherwise functional protein is observed
in a few eukaryotic proteins, such as the methyltransferase
cM.SpoI from Schizosaccharomyces pombe (single amino acid
Figure 5. The Activity of the Reactivated Deacetylase Cep15 N164H
Activity of Cep15 N164H with chloroeremomycin pseudoaglycone 3 moni-
tored by LC/ESI-MS.480 Chemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier Ltdinsertion) (Pinarbasi et al., 1996) and the L subunit of
potato ADP-glucose pyrophosphorylase (two point mutations)
(Ballicora et al., 2005). However, to our knowledge, Cep15 is
the first example of a single nucleotide mutation to reactivate
an ancestral enzymatic role for a bacterial protein.
If Cep15 is an inactive deacetylase encoded by the chloroere-
momycin gene cluster, it might be expected that it evolved from
an active chloroeremomycin N-acetylglucosaminyl deacetylase
and would previously have been optimized for activity toward
this substrate. This hypothesis was examined by a competitive
assay using equimolar teicoplanin and chloroeremomycin
N-acetylglucosaminyl pseudoaglycones 1 and 2 (55 mM each).
Analysis by LC/ESI-MS using selective ion monitoring (SIM) indi-
cates a strong preference for the teicoplanin substrate 1, which
is 60% deacetylated, compared with 1% deacetylation of
chloroeremomycin derivative 2 (Figure 6).
DISCUSSION
A full understanding of the biosynthesis of clinically important
secondary metabolites is prerequisite to rationally engineering
novel derivatives. The glycopeptides are medicinally indispens-
able antibiotics produced by the actinomycetes. Glycopeptide
biosynthesis has been heavily studied (Hubbard and Walsh,
2003), yet a number of genes remain unclassified. Recently,
COG2120 domain proteins encoded by the teicoplanin and
A40926 gene clusters have been characterized as deacetylases
essential in the biosynthesis of medicinally important N-acylglu-
cosaminyl groups (Truman et al., 2006; Ho et al., 2006). We have
confirmed this in vitro assignment by inactivating orf2* in the
teicoplanin gene cluster, to our knowledge the first gene inacti-
vation study performed in A. teichomyceticus.
The importance of the N-acyl chain is two fold. First, lipidated
glycopeptides anchor themselves to the bacterial cell mem-
brane, thus increasing the local concentration of the antibiotic
near the peptidoglycan (Beauregard et al., 1995), the antibacte-
rial target for glycopeptides. Second, teicoplanin’s activity
toward the vancomycin-resistant enterococci (VRE) VanB phe-
notype has been attributed to its acyl chain (Dong et al., 2002),
and a vancomycin derivative decorated with N-acylglucosamine
at aa 4 possesses activity toward the VRE VanB phenotype
(Thayer and Wong, 2006). An understanding of the biosynthesis
of this acylated sugar should therefore facilitate the engineered
biosynthesis of clinically useful glycopeptides.
Surprisingly, COG2120 domain proteins are also encoded by
the chloroeremomycin and balhimycin gene clusters (Cep15
and Bal2), yet these glycopeptides do not contain an N-acylglu-
cosaminyl appendage, and deacetylation is not required for the
biosynthesis of these glycopeptides. It was initially reported that
these proteins are nucleotidyltransferases (Ho et al., 2006), but
we have determined that they possess no catalytic activity,
despite high sequence identity to active deacetylases. Instead,
we have identified a single nucleotide variation that has been
sufficient to inactivate Cep15 and Bal2 from their original cata-
lytic roles. We have therefore been able to reconstitute an ances-
tral catalytic role for a bacterial protein by a single nucleotide
mutation to generate Cep15 N164H. The presence of minimally
inactivated genes in the gene clusters of bacterial secondary
metabolites suggests a latent functionality that may be exploitedAll rights reserved
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genes may indicate the evolutionary origin of a gene cluster.
Interestingly, the catalytic specificity of Cep15 N164H indi-
cates that if Cep15 had a functional ancestor, it is unlikely to
have acted on a chloroeremomycin-like scaffold. One possibility
is that the gene originates from a teicoplanin-like gene cluster,
where it was deactivated before horizontal gene transfer to a van-
comycin-like gene cluster. A possible origin could be from the
gene cluster of a teicoplanin-like glycopeptide that has no
N-acetylglucosamine-derived sugars. Examples include ristoce-
tin and actaplanin (Nicolaou et al., 1999). Analysis of the Cep15
homolog encoded by the ristocetin gene cluster (Stefan Pelzer,
personal communication) reveals that this protein also contains
the atypical asparagine residue, so it is predicted to be an inac-
tive deacetylase. Nevertheless, it shares greatest overall homol-
ogy to the functional teicoplanin pathway deacetylase, Orf2*.
Therefore, the ristocetin homolog may represent an evolutionary
‘‘missing link’’ between Orf2* and Cep15.
In eukaryotes, the retention of a catalytically incompetent gene
product is widely observed when a functional homolog is
encoded elsewhere in the genome, and such genes often have
an important regulatory role. However, no such functional coun-
terpart of cep15 or bal2 has been identified, and the deletion of
bal2 resulted in no detectable change in phenotype. Hence, we
cannot yet coherently rationalize the presence of these genes
in the cep, bal, and ristocetin clusters, or the high sequence con-
servation of these apparently inactive genes; ordinarily, bacteria
are highly adept at truncating and eventually removing function-
less genes (‘‘pseudogenes’’) to maintain their elegantly compact
genomes (Mira et al., 2001).
It is worth noting that the protein has been inactivated in the
most efficient way—a one nucleotide mutation that specifically
affects the active site. This tantalizingly suggests that the
Figure 6. Competitive Deacetylation of
Pseudoaglycones 1 and 3 with Cep15
N164H
As a result of overlapping peaks in the HPLC
spectrum, the relative rates of deacetylation are
observed using selective ion monitoring for the
appropriate substrates and products.
H164N mutation is an evolutionarily ben-
eficial (or neutral) mutation that does not
affect the protein’s tertiary structure.
Therefore, despite the evidence for inac-
tivity obtained thus far, we cannot rule
out an unidentified existing role for
Cep15 and Bal2. Another possibility is
that this is an evolutionary snapshot and
that the genes are in the process of being
removed from their clusters, a hypothesis
that may be applied to the many inactive
domains found in polyketide synthases
(Tang et al., 1998). However, it is unlikely
that this is a relatively recent mutation
followed by gene cluster divergence
between the cep and bal clusters, as
a comparative evolutionary analysis of
these clusters (Donadio et al., 2005) revealed a divergence in
GC-content and intergenic sequences, implying a relatively
ancient common origin.
One hypothesis for certain eukaryotic pseudogenes, espe-
cially those in yeast, is that they are a ‘‘resurrectable reservoir
of extra parts for environmental response’’ (Harrison and
Gerstein, 2002). Our data suggest that cep15 and bal2 may be
rare examples of a bacterial genetic reservoir, although the
mechanism by which these genes could be retained and poten-
tially reactivated remains undetermined. It is possible that poten-
tially inactivated redundant genes may feature in a number of
gene clusters for bacterial secondary metabolites. For example,
the ribostamycin gene cluster appears to encode a superfluous
glycosyltransferase (RibF) that, if active, would be predicted to
attach a further sugar onto ribostamycin (J.B.S. and Q.F., unpub-
lished data). As with cep15, ribF does not appear to be heavily
mutated and/or truncated. Further genetic and functional studies
will be required to elucidate the role of such putatively function-
less genes.
SIGNIFICANCE
The glycopeptide antibiotics are invaluable for the treatment
of multidrug-resistant bacterial infections. There is consid-
erable interest in the biosynthesis of these natural products,
because it potentially opens the way to making novel glyco-
peptide antibiotics by bioengineering. Recently, it was
claimed that the pathway to one of the sugars found in the
glycopeptide chloroeremomycin involves a dedicated glu-
cose-1-phosphate thymidylyltransferase (Cep15). This activ-
ity is unusual sinceweandothers have shown that homologs
ofCep15are zinc(II)-dependent deacetylases responsible for
cleaving the acetyl unit from N-acetylglucosamine moieties.Chemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier Ltd All rights reserved 481
Chemistry & Biology
Reactivating an Ancestral Catalytic FunctionIntriguingly, chloroeremomycin does not contain glucos-
amine, so its biosynthetic pathway does not require a
deacetylase.
In this study,we report thatCep15 is not a glucose-1-phos-
phate thymidylyltransferase but a redundant, minimally
deactivated deacetylase. This characterization is the result
of both in vivo and in vitro functional analysis. A single point
mutation has been shown to reactivate the protein product
of cep15 into an N-acetylglucosaminyl deacetylase, its likely
ancestral role.Suchminimalmutagenesis to reactivateabac-
terial gene is unprecedented and indicates that other mini-
mally mutated genes may be commonplace in bacterial
secondary metabolite gene clusters. The substrate specific-
ity of this reactivated deacetylase implies an unusual evo-
lutionary origin, while its activity with a vancomycin-like
substrate indicates that the directed biosynthesis of N-acyl-
glucosaminyl vancomycin derivatives may be possible.
EXPERIMENTAL PROCEDURES
Strains
Escherichia coli DH10B (GIBCO-BRL), Novablue (Novagen), XL1-Blue (Strata-
gene), and ET12567 (dam, dcm) strains were used for general cloning;
BL21(DE3) (Novagen) was used for protein expression; and ET12567/
pUZ8002 strain was used as a donor strain for conjugation into A. teichomyce-
ticus. A. teichomyceticus ATCC 31121 was maintained on SFM solid medium.
Amycolatopsis balhimycina strains were grown in R5 medium (Kieser et al.,
2000) at 30C supplemented with 50 mg ml1 erythromycin to select for strains
carrying integrated pSP1-derivatives.
Chemicals
Teicoplanin was purchased from Advanced Separation Technologies Ltd.,
acetonitrile (HPLC grade) was purchased from Fisher Scientific, and all other
chemicals were purchased from Sigma-Aldrich and were of analytical grade.
Teicoplanin N-acetylglucosaminyl pseudoaglycone (1) was enzymatically pro-
duced using a previously reported procedure (Truman et al., 2006). Vancomy-
cin aglycone was generated by the acid-catalyzed degradation of vancomycin
and teicoplanins A3-1 and A3-2 were generously donated by Dudley Williams.
Vancomycin N-acetylglucosaminyl pseudoaglycone (3) was enzymatically
generated using GtfB. Briefly, GtfB (30 mM), UDP-N-acetylglucosamine
(2 mM), vancomycin aglycone (1 mM), and MgCl2 (2.5 mM) in Tris-HCl buffer
(50 mM [pH 8.4]) were incubated at 37C for 24 hr. The crude mixture was
purified by HPLC using a Phenomenex Synergi Polar-RP column (250 mm 3
10 mm; 4 mm), eluting with a linear gradient of 0 to 60% acetonitrile (0.1%
TFA) in water (0.1% TFA) over 30 min with a flow rate of 2.5 ml min1.
MS: m/z (%): 1346.3670 (100) [M + H]+ (predicted [M + H]+ = 1346.3621).
Glycopeptide LC/ESI-MS Data Acquisition
Spectra were obtained using a Hewlett-Packard HPLC 1100 series instrument
coupled to a Finnigan MAT LCQ ion trap mass spectrometer fitted with a pos-
itive mode ESI source. Samples were injected onto a Phenomenex Luna
C18(2) column (250 mm 3 2.0 mm; 5 mm), eluting with a linear gradient of
0 to 60% acetonitrile (0.1% TFA) in water (0.1% TFA) over 30 min with a flow
rate of 0.3 ml min1.
Gene Expression
The cep15 gene was amplified by PCR from cosmid DNA (pCZA361) using
primers cep15-for and cep15-rev (all primers are listed in Table S1) that intro-
duced NdeI and XhoI restriction sites, respectively. After digestion, the
product was ligated into the corresponding sites in pET28(a)+. N-terminally
His6-tagged Cep15 was expressed using E. coli BL21(DE3) and was purified
by previously described procedures (Truman et al., 2006) to yield 30 mg of
purified soluble protein from 1 l of culture. The protein mass was determined
to be 31,879 Da by LC/ESI-MS. The predicted mass is 31,881 Da (His6-tagged
protein after loss of N-terminal formyl-methionine).482 Chemistry & Biology 15, 476–484, May 2008 ª2008 Elsevier LtdThe gtfB gene was amplified by PCR from cosmid DNA (pCZA361) using
primers gtfB-for and gtfB-rev that introduced NdeI and EcoRI restriction sites,
respectively. Expression yielded 15 mg of purified N-terminally His6-tagged
GtfB per liter of culture. The cloning and expression of Orf2* has been reported
elsewhere (Truman et al., 2006).
Generation of Orf2* H164N and Cep15 N164H
Mutants were constructed using primers orf2*-HN-for/orf2*-HN-rev and
cep15-NH-for/cep15-NH-rev. Mutant constructs were verified by sequencing
then expressed as detailed above. The mass of Orf2* H164N was determined
to be 32,075 Da by LC/ESI-MS (predicted mass = 32,076 Da). The mass of
Cep15 N164H was determined to be 31,903 Da by LC/ESI-MS (predicted
mass = 31,904 Da).
Nucleotidyltransferase Assay for Cep15 Fractions
Preliminary nucleotidyltransferase activity was tested by incubating Cep15
(50 mM) with UTP or TTP (1 mM) and glucose-1-phosphate (varied between
50 mM and 0.5 mM) in Tris-HCl (50 mM [pH 7.4 or 8.4]) containing MgCl2
(2.5 mM) at 30 or 37C for 16 hr. Fractional analysis of Cep15 was performed
as follows: Cep15 was eluted off a HisBind resin column (Novagen) at 4C
with a stepwise increases in imidazole concentrations (10, 50, 100, 200, and
500 mM and 1 M), and then the buffer was exchanged to Tris-HCl (50 mM
[pH 8.4]). In a total of 50 ml, each fraction (50 mM protein) was incubated with
TTP (2 mM) and glucose-1-phosphate (2 mM) in HEPES (20 mM [pH 8]) con-
taining MgCl2 (5 mM) at 25 and 37
C for 16 hr. Fractions 200 mM, 500 mM,
and 1 M were combined and purified by size exclusion chromatography,
and this sample was assayed for nucleotidyltransferase activity. Products
were assayed by LC/ESI-MS using a previously described procedure (Truman
et al., 2006).
Cep15 and Orf2* H164N Deacetylation/Deacylation Assays
In a typical assay (50 ml total volume), protein (60 mM) was incubated with
teicoplanin or 1 (0.5 mM) in Tris-HCl (50 mM [pH 8.4]) at 30C or 37C for 16
hr. In addition, various additives (e.g., metal ions, glycerol, and DMSO) were
tested for their effect on activity. All assays were quenched with acetonitrile
(50 ml) and were directly subjected to LC/ESI-MS analysis.
Cep15 N164H Competitive Deacetylation Assay
In a total reaction volume of 25 ml, Cep15 N164H (50 mM) was incubated with 1
and 2 (55 mM each) in Tris-HCl (50 mM [pH 8.4]) at 37C for 10 min. The assay
was quenched by addition of cold acetonitrile (25 ml) and was directly
subjected to LC/ESI-MS analysis.
Dorf2* Mutant Construction
The deletion plasmid, pQZ12, was based on pHZ1358 (Sun et al., 2002). A
4301 bp BamHI fragment from cosmid 4B2 containing orf2* was first cloned
into the BamHI site of pBluescript II KS+ vector (Stratagene). The resultant
plasmid was digested with PflMI to make an in-frame deletion of 285 bp in
orf2*. Digestion was followed by blunt-ending and self-religation. A 4054 bp
XbaI-EcoRV blunt-ended fragment was then excised and inserted into
EcoRV-digested pYH7 to form pQZ12.
Plasmid pQZ12 was introduced intoA. teichomyceticus through conjugation
with ET12567/pUZ8002 on SFM plates. Plates were incubated at 37C for 20
hr before being overlaid to a final concentration of 10 mg ml1 apramycin and
25 mg ml1 nalidixic acid, and then were incubated at 30C. Exconjugants were
verified on SFM plates with 20 mg ml1 apramycin and 25 mg ml1 nalidixic
acid. Confirmed colonies were then propagated on SFM plates without antibi-
otics to allow the double crossover. Colonies from these plates with sensitivity
to 10 mg ml1 apramycin were PCR screened using primers Dorf2*-for and
Dorf2*-rev. A 767 bp PCR product was sequenced to confirm the in-frame
deletion.
A. teichomyceticus was fermented in standard conditions for teicoplanin
production. Five-day-old fermentation culture was harvested by centrifugation
and the glycopeptide was purified using a D-alanine-D-alanine column with
a flow rate of approximately 0.5 ml min1. The resulting eluate was subjected
to LC/ESI-MS analysis.All rights reserved
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The complementation plasmid, pQZ20, was constructed by inserting a 1407 bp
PvuII-SfoI fragment, containing orf2* and its natural promoter, into the
integrative vector pSET152 (Bierman et al., 1992). As a control, conjugation
was also performed as described with the empty vector pSET152.
Construction and Analysis of Dbal2 Mutant
The plasmid pSPDorf2 was constructed to inactivate bal2 by an in-frame
deletion of 219 bp. A 1364 bp upstream (frDorf2-left) and a 1304 bp
downstream fragment (frDorf2-right) of bal2 were amplified by PCR from
cosmid DNA using the primers prDorf2F1.1/prDorf2F1.2 and prDorf2F2.1/
prDorf2F2.2, respectively. The primers contained restriction sites at the 30
and 50 ends (SphI/XbaI and XbaI/EcoRI). Both fragments were cloned into
the vector pSP1 to generate pSPDorf2.
The wild-type strain A. balhimycina was transformed with pSPDorf2 by
means of a modified direct transformation (Pelzer et al., 1997). The integration
of the plasmid via homologous recombination into the chromosome was con-
firmed by PCR screening for the erythromycin resistance cassette using
primers ermEleft and ermEright. To obtain a deletion mutant, a second homol-
ogous recombination event was provoked by stressing nonproducing colonies
as described elsewhere (Puk et al., 2002). Colonies were examined for sensi-
tivity toward erythromycin, and the deletion was verified by PCR analysis using
primers prDorf2.1prove and prDorf2.2prove to generate a 3031 bp fragment
from the A. balhimycinaDbal2 mutant. Balhimycin production was determined
by bioassays using Bacillus subtilis ATCC 6633.
SUPPLEMENTAL DATA
Supplemental Data include three figures and one table and can be found
with this article online at http://www.chembiol.com/cgi/content/full/15/5/
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